Research article

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa

Anand Reddi^{* 1} , Sarah C Leeper^{* 2} , Anneke C Grobler³ , Rosemary Geddes⁴ , K Holly France¹ , Gillian L Dorse¹ , Willem J Vlok¹ , Mbali Mntambo¹ , Monty Thomas¹ , Kristy Nixon¹ , Helga L Holst¹ , Quarraisha Abdool Karim³ , Nigel C Rollins⁵ , Hoosen M Coovadia⁶ and Janet Giddy¹

¹Sinikithemba HIV/AIDS Clinic, McCord Hospital, Durban, South Africa

²Children's Rights Centre, Durban, South Africa

³CAPRISA, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

⁴Department of Community Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

⁵Department of Paediatrics and Child Health, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

⁶Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

author email corresponding author email* Contributed equally

BMC Pediatrics 2007, 7:13doi:10.1186/1471-2431-7-13

Published:	17 March 2007

Abstract

Background

Few studies address the use of paediatric highly active antiretroviral therapy (HAART) in Africa.

Methods

We performed a retrospective cohort study to investigate preliminary outcomes of all children eligible for HAART at Sinikithemba HIV/AIDS clinic in KwaZulu-Natal, South Africa. Immunologic, virologic, clinical, mortality, primary caregiver, and psychosocial variables were collected and analyzed.

Results

From August 31, 2003 until October 31, 2005, 151 children initiated HAART. The median age at HAART initiation was 5.7 years (range 0.3–15.4). Median follow-up time of the cohort after HAART initiation was 8 months (IQR 3.5–13.5). The median change in CD4% from baseline (p < 0.001) was 10.2 (IQR 5.0–13.8) at 6 months (n = 90), and 16.2 (IQR 9.6–20.3) at 12 months (n = 59). Viral loads (VLs) were available for 100 children at 6 months of which 84% had HIV-1 RNA levels ≤ 50 copies/mL. At 12 months, 80.3% (n = 61) had undetectable VLs. Sixty-five out of 88 children (73.8%) reported a significant increase (p < 0.001) in weight after the first month. Eighty-nine percent of the cohort (n = 132) reported ≤ 2 missed doses during any given treatment month (> 95%adherence). Seventeen patients (11.3%) had a regimen change; two (1.3%) were due to antiretroviral toxicity. The Kaplan-Meier one year survival estimate was 90.9% (95%confidence interval (CI) 84.8–94.6). Thirteen children died during follow-up (8.6%), one changed service provider, and no children were lost to follow-up. All 13 deaths occurred in children with advanced HIV disease within 5 months of treatment initiation. In multivariate analysis of baseline variables against mortality using Cox proportional-hazards model, chronic gastroenteritis was associated with death [hazard ratio (HR), 12.34; 95%CI, 1.27–119.71) and an HIV-positive primary caregiver was found to be protective against mortality [HR, 0.12; 95%CI, 0.02–0.88). Age, orphanhood, baseline CD4%, and hemoglobin were not predicators of mortality in our cohort. Fifty-two percent of the cohort had at least one HIV-positive primary caregiver, and 38.4% had at least one primary caregiver also on HAART at Sinikithemba clinic.

Conclusion

This report suggests that paediatric HAART can be effective despite the challenges of a resource-limited setting.